OSE Immunotherapeutics Announces Completion of Patient Enrollment in Phase 2 Trial for Tedopi® in Combination with Nivolumab or Docetaxel for NSCLC
OSE Immunotherapeutics SA has completed patient enrollment in the Combi-TED Phase 2 clinical trial, evaluating the cancer vaccine Tedopi® with nivolumab or docetaxel for metastatic Non-Small Cell Lung Cancer (NSCLC). The trial includes 105 HLA-A2 positive patients across Italy, France, and Spain, with a primary endpoint of 1-year survival rate. Top-line results are expected in the second half of 2026.
OSE Immunotherapeutics SA, in collaboration with the FoRT Foundation, has announced the completion of patient enrollment in the Combi-TED Phase 2 clinical trial. This study is evaluating the neoepitope-based therapeutic cancer vaccine Tedopi® in combination with either the anti-PD1 immune checkpoint inhibitor nivolumab or the chemotherapy agent docetaxel, as a second-line treatment for patients with metastatic Non-Small Cell Lung Cancer (NSCLC). A total of 105 HLA-A2 positive patients are participating in the trial, which is being conducted across sites in Italy, France, and Spain. The primary endpoint is the 1-year survival rate. The top-line results of this study are expected to be presented in the second half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001127537-en) on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
